At the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL, the final results of phase 2 trial of LCL161 for myelofibrosis (MF) were presented by Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX. Here Dr Pemmaraju discusses the findings from the use of this novel oral SMAC mimetic/IAP antagonist in intermediate to high-risk MF (NCT02098161).